Cargando…
Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment
Antibody–drug conjugates (ADCs) are a class of antineoplastic agents whose structure is composed of three main components: a monoclonal antibody (mAB) targeting a specific target antigen, a cytotoxic payload, and a linker binding the antibody to the payload. By combining the specificity of mABs with...
Autores principales: | Nader-Marta, Guilherme, Molinelli, Chiara, Debien, Véronique, Martins-Branco, Diogo, Aftimos, Philippe, de Azambuja, Evandro, Awada, Ahmad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331351/ https://www.ncbi.nlm.nih.gov/pubmed/37435563 http://dx.doi.org/10.1177/17588359231183679 |
Ejemplares similares
-
Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis
por: Martins-Branco, Diogo, et al.
Publicado: (2022) -
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021) -
Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer
por: Agostinetto, Elisa, et al.
Publicado: (2022) -
Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience
por: Franzoi, Maria Alice, et al.
Publicado: (2021) -
How we treat patients with metastatic HER2-positive breast cancer
por: Nader-Marta, G., et al.
Publicado: (2022)